PT  - JOURNAL ARTICLE
AU  - Mendel, Arielle
AU  - Ennis, Daniel
AU  - Go, Ellen
AU  - Bakowsky, Volodko
AU  - Baldwin, Corisande
AU  - Benseler, Susanne M. 
AU  - Cabral, David A. 
AU  - Carette, Simon
AU  - Clements-Baker, Marie
AU  - Clifford, Alison
AU  - Cohen Tervaert, Jan Willem 
AU  - Cox, Gerard
AU  - Dehghan, Natasha
AU  - Dipchand, Christine
AU  - Dhindsa, Navjot
AU  - Famorca, Leilani
AU  - Fifi-Mah, Aurore
AU  - Garner, Stephanie
AU  - Girard, Louis-Philippe
AU  - Lessard, Clode
AU  - Liang, Patrick
AU  - Noone, Damien
AU  - Makhzoum, Jean-Paul
AU  - Milman, Nataliya
AU  - Pineau, Christian A. 
AU  - Reich, Heather N. 
AU  - Rhéaume, Maxime
AU  - Robinson, David B. 
AU  - Rumsey, Dax G. 
AU  - Towheed, Tanveer E. 
AU  - Trudeau, Judith
AU  - Twilt, Marinka
AU  - Yacyshyn, Elaine
AU  - Yeung, Rae
AU  - Barra, Lillian
AU  - Khalidi, Nader
AU  - Pagnoux, Christian
TI  - CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update
AID  - 10.3899/jrheum.200721
DP  - 2020 Sep 15
TA  - The Journal of Rheumatology
PG  - jrheum.200721
4099  - http://www.jrheum.org/content/early/2020/09/10/jrheum.200721.short
4100  - http://www.jrheum.org/content/early/2020/09/10/jrheum.200721.full
AB  - Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada. The current update aimed to revise existing recommendations and create additional recommendations, as needed, based on a review of new available evidence. Methods A needs assessment survey of CanVasc members informed questions for an updated systematic literature review (publications spanning May 2014-September 2019) using Medline, Embase, and Cochrane. New and revised recommendations were developed and categorized according to the level of evidence and strength of each recommendation. The CanVasc working group used a two-step modified Delphi procedure to reach >80% consensus on the inclusion, wording and grading of each new and revised recommendation. Results Eleven new and 16 revised recommendations were created, and 12 original (2015) recommendations were retained. New and revised recommendations are discussed in detail within this document. Five original recommendations were removed, of which 4 were incorporated into the explanatory text. The supplementary appendix for practical use was revised to reflect the updated recommendations. Conclusion The 2020 updated recommendations provide rheumatologists, nephrologists, and other specialists caring for patients with AAV in Canada with new management guidance, based on current evidence and consensus from Canadian experts.